Abstract
Purpose This study aims to evaluate the average motility of the implant and custom-made prosthesis after MES, the surgical duration, and the complications encountered during the procedure at a tertiary eye hospital. Methods This was a prospective, non-randomized interventional study. The muscles were sutured to the fornices before the enucleation of the eyeball to minimize surgical time and the need for additional sutures. 35 consecutive patients meeting the inclusion criteria were enrolled in the study. Data on surgery time, complication rates, and implant/prosthesis motility were recorded and analyzed. Results The mean surgery duration was 39.3 ± 3.76 minutes. The mean movement of the PMMA implant was 2.34 mm in elevation, 2.25 mm in depression, 2.74 mm in abduction, and 2.71 mm in adduction. The mean movement of the custom-made prosthesis was 2.45 mm in elevation, 2.62 mm in depression, 2.74 mm in adduction, and 2.82 mm in abduction. Complications were minimal: one intraoperative superior rectus slippage, few cases with early postoperative nausea, vomiting, and headache, all resolving within a week. At six weeks, one case each of suture granuloma and shallow inferior fornix was noted and managed successfully. Patient satisfaction was high (91.94%), with a mean score of 4.25 ± 0.65. Minimal dissatisfaction was linked to low motility or mild socket contraction. Conclusion Myoconjunctival enucleation offers favorable implant and prosthesis motility, a relatively short surgical duration, and minimal complications. High patient satisfaction further supports its efficacy as a reliable enucleation technique.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical Committee of Nepal health research council(NHRC) gave ethical approval for this study on 10th may 2023 with ref no 3054
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.